Brian Kearns
Senior Vice President of Business Development and Investor Relations
Replay available
Globus Medical, Inc. Class A (NYSE: GMED) Q2 2026 earnings conference call, held 2026-08-06. Replay captured from the company's public earnings webcast.

Senior Vice President of Business Development and Investor Relations
President and Chief Executive Officer
Chief Financial Officer
Analyst, Wells Fargo
Analyst, BMO Capital Markets
Analyst, Jefferies
Analyst, Canaccord Genuity
Analyst, Steeple
Welcome to Globus Medical's second quarter 2026 earnings call. At this time, all lines will be on mute and a Q&A session will be held after the prepared remarks. I will now turn the call over to Brian Kearns, Senior Vice President of Business Development and Investor Relations. Mr. Kearns, please go ahead. Thank you, Sarah, and thank you everyone for being with us today. Joining today's call from Globus Medical will be Keith Pfeil, President and Chief Executive Officer, and Kyle Klin, Chief Financial Officer. This review is being made available via webcast, accessible through the Investor Relations section of the Globus Medical website at www.globusmedical.com. Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements. Our Form 10-K for the 2025 fiscal year and our subsequent filings with the Securities and Exchange Commission identify certain factors that could cause our actual results to differ materially from those projected in any forward-looking statements made today. Our SEC filings, including the 10-K, are available on our website. We do not undertake to update any forward-looking statements as a result of new information or future events or developments. Our discussion today will also include certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We believe these non-GAAP financial measures provide additional information pertinent to our business performance. These non-GAAP financial measures should not be considered replacements for and should be read together with the most directly comparable GAAP financial measures. Reconciliations to the most directly comparable gap measures are available in the schedules accomp...